Sugi Predict

Sugi Predict / Compounds / SCHEMBL9938469

SCHEMBL9938469

SCHEMBL9938469

COC(=O)c1ccc(Cc2cccc(F)c2)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.50
▸ L3MBTL1 Q9Y468 2/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ SNCA P37840 1/20 0.49
▸ MRGPRX4 Q96LA9 1/20 0.47
▸ PARP1 P09874 1/20 0.46
▸ HCAR2 Q8TDS4 1/20 0.43
▸ TP53 P04637 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ CYP4F2 P78329 1/20 0.42
▸ CYP4A11 Q02928 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ NR3C2 P08235 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ MAOB P27338 2/20 0.41
▸ MAOA P21397 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16709815 0.87 CHEK1 (0.47) MAPK1L3MBTL1KDM4EALDH1A1HPGD
SCHEMBL753810 0.85 MAPK1 (0.53) MAPK1L3MBTL1KDM4EALDH1A1HPGD
SCHEMBL21384039 0.84 LMNA (0.47) MAPK1L3MBTL1KDM4EALDH1A1HPGD
SCHEMBL21384222 0.84 MAPK1 (0.49) MAPK1L3MBTL1KDM4EALDH1A1HPGD
SCHEMBL29442799 0.83 HCAR2 (0.57) L3MBTL1KDM4EALDH1A1SNCAHCAR2
SCHEMBL9938749 0.83 HCAR2 (0.57) L3MBTL1KDM4EALDH1A1SNCAHCAR2
SCHEMBL11630275 0.83 MAPK1 (0.54) MAPK1L3MBTL1KDM4EPARP1
SCHEMBL21384012 0.82 PARP1 (0.45) MAPK1L3MBTL1KDM4ESNCAMRGPRX4
SCHEMBL11393841 0.81 P4HTM (0.54) KDM4EALDH1A1HPGDMRGPRX4TP53
SCHEMBL9938980 0.79 KMT2A (0.56) MAPK1L3MBTL1KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12180221-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-12-31 — — US disclosed
CN-118084801-A Compounds and uses thereof 詹森药业有限公司 2024-05-28 — — CN disclosed
CN-118084800-A Compounds and uses thereof 詹森药业有限公司 2024-05-28 — — CN disclosed
CN-112312913-B Compounds and uses thereof 詹森药业有限公司 2024-03-08 — — CN disclosed
US-20230078764-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2023-03-16 — — US disclosed
US-20220298168-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2022-09-22 — — US disclosed
CN-114174273-A Compounds and uses thereof 优曼尼蒂治疗公司 2022-03-11 — — CN disclosed
EP-3941908-A1 COMPOUNDS AND USES THEREOF Yumanity Therapeutics, Inc. (US) 2022-01-26 — — EP disclosed
CN-112312913-A Compounds and uses thereof 优曼尼蒂治疗公司 2021-02-02 — — CN disclosed
EP-3768269-A1 COMPOUNDS AND USES THEREOF Yumanity Therapeutics, Inc. (US) 2021-01-27 — — EP disclosed
WO-2020198026-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-10-01 — — WO disclosed
WO-2019183587-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2019-09-26 — — WO disclosed
WO-2019183587-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2019-09-26 — — WO disclosed
EP-2651888-B1 N-((1H-indol-3-yl)-alkyl)-4-benzyl)benzamide and N-((1H-pyrrolo[2,3-b]pyridin-3-yl)-alkyl)-4-benzyl)benzamide derivatives as alpha synuclein aggregation inhibitors for the treatment of neurodegenerative disorders UNIV LEUVEN KATH (BE) 2017-05-17 — — EP disclosed
CN-103261156-B For treating the noval chemical compound of neurodegenerative disease 鲁汶天主教大学研究开发部 2016-12-28 — — CN disclosed
US-9266832-B2 Compounds for the treatment of neurodegenerative diseases Katholieke Universiteit Levun (BE) 2016-02-23 — — US disclosed
EP-2651888-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES Katholieke Universiteit Leuven K.U. Leuven R&D (BE) 2013-10-23 — — EP disclosed
US-20130274260-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND (BE) 2013-10-17 — — US disclosed
CN-103261156-A New compounds for the treatment of neurodegenerative diseases LEUVEN K U RES & DEV 2013-08-21 — — CN disclosed
WO-2012080221-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274260-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, PSEN1 MAPK1 2832/4885L3MBTL1 167/4885KDM4E 2195/4885
US-20230078764-A1 COMPOUNDS AND USES THEREOF NLN, BDNF, NQO1 MAPK1 3871/4885L3MBTL1 3090/4885KDM4E 1073/4885
US-20220298168-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 MAPK1 4304/4885L3MBTL1 3366/4885KDM4E 2853/4885
US-12180221-B2 Compounds and uses thereof NLN, ACHE, CLN6 MAPK1 4304/4885L3MBTL1 3366/4885KDM4E 2853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.